The report highlights that insulin-derived amyloidosis can mimic other injection-site reactions and should be considered when ...
Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery ...
Repeated insulin shots at the same site can seed amyloid; consider this diagnosis if absorption seems erratic or glucose control worsens with a persistent lump.
A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback